# Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

> **NCT03905707** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Zealand Pharma** · enrollment: 145 (estimated)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** glepaglutide

## Key facts

- **NCT ID:** NCT03905707
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-07
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905707, "Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03905707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*